CRISPR Therapeutics AG
NASDAQ: CRSP
$44.25
-$0.18 (-0.41%)
Closing Price on June 20, 2025
CRSP Stock Chart and Intraday Price
CRSP Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Address | BAARERSTRASSE 14, ZUG, CH |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 6,723.12M USD |
| Shares Outstanding | 80,276,000 |
CRSP Articles
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level of...
Published:
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor...
Published:
The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The tech sector has been the driving force for the stock market’s...
Published:
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT) split its stock in February,...
Published:
Cathie Wood is the founder and CEO of Ark Invest, an asset management firm focusing on disruptive innovation, with approximately $14 billion in assets across six actively managed ETFs, two index...
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Published:
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Published:
Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery. But what if, instead of the scalpel, you could invest in a company with the...
Published:
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Published:
Wednesday's top analyst upgrades and downgrades included Abbott Laboratories, Boston Scientific, ChargePoint, Coinbase Global, Dollar General, Equitrans Midstream, Ford, Hasbro, Johnson & Johnson,...
Published:
Friday's top analyst upgrades and downgrades included American Airlines, Broadcom, Chevron, DraftKings, Enphase Energy, EOG Resources, Exxon Mobil, First Solar, Hertz Global, LyondellBasell...
Published:
Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.
Published:
Tuesday's additional top analyst upgrades and downgrades were on Bed Bath & Beyond, Clorox, CRISPR Therapeutics, LivePerson, Nike, Palantir Technologies, Tyson Foods and more.
Published:
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Published:
